Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
  • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K31/728—Hyaluronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/193—Colony stimulating factors [CSF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/53—Colony-stimulating factor [CSF]
  • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
  • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
  • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Definitions

• the present invention relates to a combination and/or combined use of a sulphated hyaluronan oligomer and/or polymer and at least one factor ca- 5 pable of releasing stem cells.
• the present invention also relates to a use of the combination to repair blood count and/or alter the relative amounts of blood cells and/or the types of blood cells in a subject. Further, the present invention relates to a use of the combination to mobilize stem cells to the bloodstream.
• the present invention additionally relates to a use of a non-sulphated and/or a 10 sulphated hyaluronan oligomer and/or polymer to repair blood count and/or alter the relative amounts of blood cells and/or the types of blood cells in a subject.
• the present invention also relates to sulphated and/or non-sulphated hyaluronan oligomers and/or polymers.
• PBSC peripheral blood stem cells
• Factors and/or agents capable of releasing stem cells from the site of origin, typically bone marrow, are used to mobilize stem cells into circulation
• Cytokines such as, granulocyte-colony-stimulating factor (G-CSF) and granulocyte- macrophage colony-stimulating factor (GM-CSF), and CXCR4-receptor inhibitors, such as, MozobilTM are examples of factors and/or agents that are capa-
• Patent application WO 2008/019371 describes a combination of G- CSF with at least one CXCR4 inhibitor and at least one CXCR2 agonist.
• the combination is used to mobilize progenitor and/or stem cells into the bloodstream of a subject.
• Patent publication US 6,875,753 describes administration of hyaluronic acid having molecular weight less than about 750 000 daltons to a stem cell donor for increasing the concentration of stem cells in the blood of the donor.
• Patent publication US 7,446,100 describes administration of hyaluronic acid having molecular weight less than about 750 000 daltons to a pa- tient for mobilizing different blood cell types, such as lymphocytes, T- and/or B- cells into the blood of the patient.
• Patent application US 2004/0204384 describes a method of regulating the differentiation of hematopoietic cells with a polymer of disaccharides comprised of an N-acetyl-D-glucosamine structure bonded by an O-glycoside ⁇ 1 -4 bond with a glucuronic acid structure.
• the present invention relates to a combination and/or combined use of at least one sulphated hyaluronan oligomer and/or polymer (a sulphated HAmer) and at least one factor capable of releasing stem cells.
• a sulphated HAmer sulphated hyaluronan oligomer and/or polymer
• the present invention relates to a combination and/or combined use of a sulphated hyaluronic acid oligomer and/or polymer (HAmer) and at least one factor capable of releasing stem cells.
• the present invention also relates to a use of at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof, to alter the relative amounts of blood cells and/or the types of blood cells in a subject.
• the present invention also relates to a use of at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof for repairing the blood count of a subject.
• the present inven- tion relates to at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof for use in repairing the blood count of a subject
• the present invention further relates to a use of at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof, to mobilize stem cells to the bloodstream of the subject.
• the present invention relates to at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof, for use in mobilizing stem cells to the bloodstream of the subject.
• the present invention relates to a method for altering the relative amounts of blood cells and/or the types of blood cells of a subject by administering at least one sulphated HAmer and at least one factor capable of releasing stem cells, or a combination thereof to said subject.
• the present invention relates to a method of mobilizing stem cells to the bloodstream of a subject by administering at least one hyaluronan oligomer and/or polymer or at least one factor capable of releasing stem cells or the combination thereof to said subject.
• the present invention also relates to a method of repairing and/or improving the blood count of a subject by administering at least one sulphated HAmer and at least one factor capable of releasing stem cells or a combination thereof to said subject.
• the present invention additionally relates to a use of at least one non-sulphated and/or a sulphated HAmer to repair blood count and/or alter the relative amounts of blood cells and/or the types of blood cells in a subject.
• the present invention relates to at least one non-sulphated and/or a sulphated HAmer for use in repairing blood count and/or in altering the relative amounts of blood cells and/or the types of blood cells in a subject.
• the present invention relates to a method of repairing the blood count and/or altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering at least one non-sulphated and/or a sulphated HAmer to said subject.
• the present invention relates to sulphated and/or non-sulphated
• Ri is an uronic acid non-reducing end group, which is GlcA or its be- ta-elimination product containing a double bond between 4- and 5-position of the uronic acid ring (delta-hexuroronic acid);
• R 2 and R 3 are independently either H or acetyl or 3-10 C-alkyl or al- kanoyl derivative of the amine or sulphate amide, the R 3 optionally varies at each position of the chain;
• R is a reducing end group, which is GlcA or its reducing end derivative including reducing (aldehyde form) and non-reducing (derivative of aldehyde) structures;
• n1 and n3 are integers being either 0 or 1 ,
• n2 is an integer varying from 2-50, preferably 4-25,
• the GlcN residue is optionally derivatized by sulphate residue at position 2 and/or 4 and/or 6, and HexA residue(s) is optionally derivatized by sulphate residue at position 2 and/or 3.
• Figure 1 shows the number of hematopoietic progenitor cells
• HPCs colony forming unit
• FIG. 2 shows the leukocyte (WBC) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representing the value from a single mouse.
• WBC leukocyte
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c, 500 ⁇ g LMW HA i.v or 500 ⁇ g LMW 6-O-S HA i.v. Samples were collected 4 hours after the injections.
• mice were treated as in A, but samples were collected either 1 , 2 or 3 days after the injections. All time-points had time- and age-matched vehicle and NeulastaTM groups.
• mice were treated as in A, but samples were collected 5 days after the injections.
• FIG. 3 shows the leukocyte (WBC) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representing the value from a single mouse.
• WBC leukocyte
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c. single injection, 500 ⁇ g LMW HA i.v administered repeatedly daily for 2 (3 doses) or 5 days (6 doses) or 500 ⁇ g LMW 6-O-S HA i.v administered repeatedly daily for 3 (3 doses) or 6 days (6 doses). Samples were collected either 3 days or 5 days after the beginning of the injections and after 4 hours after the last LMW HA injection.
• NelastaTM pegfilgrastim
• mice were treated with vehicle and pegfilgrastim (NeulastaTM) as in A and combination therapy groups received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and i.v. injections of 500 ⁇ g LMW HA or LMW 6-O-S HA administered repeatedly once daily (6 doses). Samples were collected 4 hours after the last LMW HA injection on study day 5.
• Figure 4 shows the erythrocyte (RBC) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representing the value from a single mouse.
• RBC erythrocyte
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c, 500 ⁇ g LMW HA i.v or 500 ⁇ g LMW 6-O-S HA i.v. Samples were collected
• mice were treated as in A, but samples were collected either 1 , 2 or 3 days after the injections. All time-points had time- and age-matched vehicle and NeulastaTM groups.
• mice were treated as in A, but samples were collected 5 days after the injections.
• Figure 5 shows the erythrocyte (RBC) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representing the value from a single mouse.
• RBC erythrocyte
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c. single injection, 500 ⁇ g LMW HA i.v administered repeatedly daily for 2 (3 doses) or 5 days (6 doses) or 500 ⁇ g LMW 6-O-S HA i.v administered repeatedly daily for 3 (3 doses) or 6 days (6 doses). Samples were collected either 3 days or 5 days after the beginning of the injections and after 4 hours after the last LMW HA injection.
• NelastaTM pegfilgrastim
• mice were treated with vehicle and pegfilgrastim (NeulastaTM) as in A and combination therapy groups received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and i.v. injections of 500 ⁇ g LMW HA or LMW 6-O-S HA administered repeatedly once daily (6 doses). Samples were collected 4 hours after the last LMW HA injection on study day 5.
• FIG. 6 shows the platelet (PLT) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representing the value from a single mouse.
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c, 500 ⁇ g LMW HA i.v or 500 ⁇ g LMW 6-O-S HA i.v. Samples were collected 4 hours after the injections.
• mice were treated as in A, but samples were collected either 1 , 2 or 3 days after the injections. All time-points had time- and age-matched vehicle and NeulastaTM groups.
• mice were treated as in A, but samples were collected 5 days after the injections.
• FIG. 7 shows the platelet (PLT) contents in mouse blood determined by automated blood cell counter Sysmex XT-2000i. Results are presented as scatter dot plots with means +SEM, with each point representating the value from a single mouse.
• mice were treated with vehicle, 25 ⁇ g pegfilgrastim (NeulastaTM) s.c. single injection, 500 ⁇ g LMW HA i.v administered repeatedly daily for 2 (3 doses) or 5 days (6 doses) or 500 ⁇ g LMW 6-O-S HA i.v administered repeatedly daily for 3 (3 doses) or 6 days (6 doses). Samples were collected either 3 days or 5 days after the beginning of the injections and after 4 hours after the last LMW HA injection.
• NelastaTM pegfilgrastim
• mice were treated with vehicle and pegfilgrastim (NeulastaTM) as in A and combination therapy groups received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and i.v. injections of 500 ⁇ g LMW HA or LMW 6-O-S HA administered repeatedly once daily (6 doses). Samples were collected 4 hours after the last LMW HA injection on study day 5.
• Figure 8 shows the spleen weights in C57BI/6J mice after mobilization studies. The results presented are means +SD. All time-points have time- and age-matched vehicle and pegfilgrastim (NeulastaTM) control animals.
• NeulastaTM was injected as single 25 ⁇ g doses s.c. on study day 0.
• Vehicle animals were injected with similar injection schemes as the test substances. The animals were sacrificed 4 hours after the last injection on the last experimental day.
• Figure 9 shows the number of HPCs as determined by colony forming unit (CFU) assay.
• CFU colony forming unit
• LMW HA and LMW 6-O-S HA were administered in 500 ⁇ g doses/mouse i.v. either as single doses or repeatedly once/day for 2 (3 doses) or 5 (6 doses) days.
• NeulastaTM was injected as single 25 ⁇ g doses s.c. on study day 0.
• Vehicle animals were injected with similar injection schemes as the test substances. The animals were sacrificed 4 hours after the last injection on the last experimental day.
• Figure 10 shows the number of HPCs as determined by colony forming unit (CFU) assay.
• CFU colony forming unit
• the combination therapy group (+6-O-S HA) received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and a single i.v. injection of 500 ⁇ g LMW 6-O-S HA administered 1 hour before sampling.
• B. Spleen weights in the same animals as were studied in A. Results are presented as scatter dot plots and means +SD, with each point representing the value from a single mouse +SD (n 4-6).
• Figure 1 1 shows the immunophenotypic profiling of monocytes, neutrophils and eosinophils (MNEs) in peripheral blood after mobilization studies as studied by flow cytometry.
• the cells gated in A. were further analyzed in B. and C.
• NeulastaTM was injected as single 25 ⁇ g doses s.c. on study day 0.
• the combination therapy group (+6-O-S HA) received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and a single i.v. injection of 500 ⁇ g LMW 6-O-S HA administered 1 hour before sampling.
• Figure 13 shows the immunophenotypic profiling of lymphocytes in peripheral blood after mobilization studies as studied by flow cytometry.
• the cells gated in A. were further analyzed in B-E.
• NeulastaTM was injected as single 25 ⁇ g doses s.c. on study day 0.
• the combination therapy group (+6-O- S HA) received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and a single i.v. injection of 500 ⁇ g LMW 6-O-S HA administered 1 hour before sampling.
• Figure 14 shows the amounts of SLAM+ cells (CD150+CD48- CD45+) in peripheral blood. The results are presented as means +SD of recorded positive events/50 000 analyzed cells.
• NeulastaTM was injected as single 25 ⁇ g doses s.c. on study day 0.
• the combination therapy group (+6-O- S HA) received pegfilgrastim (NeulastaTM) s.c. at day 0 (-5 days from sampling) and a single i.v. injection of 500 ⁇ g LMW 6-O-S HA administered 1 hour before sampling.
• Inset A. represents the analyzed cell population in the vehicle group
• inset B. represents the analyzed cell population in the NeulastaTM-alone and NeulastaTM + 6-O-S HA-groups.
• Figure 15 shows the fractionation of acid hydrolyzed hyaluronic acid by size exclusion HPLC on preparative Superdex column.
• Figure 16 shows the analysis of hyaluronic acid and sulfated hyaluronic acid preparates by size exclusion HPLC on Superdex 75 column.
• Figure 18 shows the sequence alignment of the following G-CSF sequences:
• DB00099 refers to filgrastim
• DB00019 refers to pegfilgrastim
• GCSFisoB refers to isoform B of G-CSF (lenograstim)
• GCSFisoA refers to isoform A of G-CSF
• GCSFisoC refers to isoform C of G-CSF
• GCsFisoD refers to isoform D of G-CS. Detailed description of the invention
• HSC Hematopoietic stem cells
• MSC Mesenchymal stem cells
• Endothelial stem cells are multipotent stem cells and one of the three types of stem cells to be found in bone marrow.
• Human embryonic stem cells hESCs
• hESCs Human embryonic stem cells
• hESCs are considered to be the building blocks for all types of cells in humans and thus have huge potential in applications of cell therapy and regenerative medicine.
• Induced pluripotent stem (iPS) cells are a type of pluripotent stem cell artificially derived from a non-pluripotent cell, typically an adult somatic cell by inducing a "forced" expression of certain genes.
• the term "stem cell” refers mainly to stem cells found in blood, and/or derived or derivable from blood, and/or releasable to blood by reagents and methods described in the invention, such as hematopoietic, mesenchymal, and/or endothelial stem cells.
• the stem cell is a hematopoietic stem.
• the stem cell is CD34+ hematopoietic stem cell.
• G-CSF granulocyte-colony-stimulating factor
• GM-CSF granulocyte-macrophage colony-stimulating factor
• MozobilTM plerixafor
• G-CSF Granulocyte-colony-stimulating factor
• WBC white blood cells
• G-CSF is used with certain cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens.
• G- CSF is also used to increase the number of hematopoietic stem cells in the bloodstream of a subject (a donor) before collecting and using the cells in stem cell transplantation.
• G-CSF may also be given to a recipient of a hematopoietic stem cell transplant.
• Filgrastim is a granulocyte colony-stimulating factor analog, specifically a recombinant methionyl human granulocyte colony-stimulating factor (r- metHuG-CSF) manufactured by recombinant DNA technology. It is currently marketed under the brand names Neupogen (Amgen), Grafeel (Dr. Reddy's Laboratories), Nugraf (Zenotech Laboratories Limited), Neukine (Intas Bio- pharmaceuticals) and Emgrast (Emcure biopharmaceuticals), for example.
• filgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant inci- dence of severe neutropenia with fever. It is also indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML and to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloabla- tive chemotherapy followed by marrow transplantation.
• Biograstim (CT Arzneimittel GmbH) is a biosimilar medicine containing filgrastim as the active substance.
• Pegfilgrastim (NeulastaTM) is a covalent conjugate of recombinant human G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule.
• Pegfilgrastim is approved by European Medicines Agency (EMA) for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
• EMA European Medicines Agency
• NeulastaTM is presently indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving rnyelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
• Lenograstim is a glycosylated recombinant human granulocyte colony-stimulating factor which has been developed by Ligand Pharmaceuticals.
• Granulocyte-macrophage colony-stimulating factor is a glycoprotein regulating the production and release of stem cells. It stimulates stem cells to produce granulocytes and monocytes.
• G-CSF granulocyte-macrophage colony-stimulating factor
• GM-CSF granulocyte-macrophage colony-stimulating factor
• CXCR4 inhibitors such as, plerixafor (MozobilTM) act by blocking CXCR4-receptors and aid in releasing stem cells into circulating blood.
• CXCR4 is a chemokine receptor that plays an important role in holding hematopoietic stem cells in the bone marrow.
• Plerixafor in combination with G-CSF is approved by European Medicines Agency (EMA) for enhancing mobilization of hematopoetic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.
• EMA European Medicines Agency
• FDA Food and Drug Administration
• Mozobil prixafor, injection
• G-CSF granulocyte-colony stimulating factor
• factor capable of mobilizing stem cells or the term “factor mobilizing stem cells” refer to a molecule, such as a cytokine and/or to a compound (an antagonist or an inhibitor) able to induce the release of stem cells by blocking a receptor, that is capable to hold stem cells in their place of origin, for example, in the bone marrow.
• the factor mobilizing stem cells is a cytokine or a CXCR4-receptor inhibitor/antagonist including therapeutically suitable and/or pharmaceutically acceptable salts, derivates, conjugates and analogs, such as, pegylated, multiply pegylated, glycopegylated and glycan conjucated variants thereof.
• the factor mobilizing stem cells into circulation is selected from the group of G-CSF, GM-CSF, CXCR4- receptor inhibitors/antagonists, their derivatives, analogs and conjugates and/or mixtures thereof.
• the present invention is directed to uses, dose regimens, methods and composition including a cytokine in combination with at least one hyaluronan oligomer and/or polymer (HAmer) according to the invention.
• the cytokine is preferably a blood cell colony stimulating factor, a CSF.
• the preferred CSF is a cytokine increasing the amount of white blood cells/ leukocytes such as neutrophils.
• the invention is directed to use of the HAmer with any form of G- CSF.
• the preferred form of G-CSF is a mammalian G-CSF such as a human, rat or mouse form of G-CSF, preferably human or mouse G-CSF.
• the preferred mammalian G-CSF molecules include natural isoforms of G-CSF such as isoforms A-D (SEQ ID NO:3 - SEQ ID NO:6), in a preferred embodiment the isoform B (SEQ ID NO:4), more preferably secreted form of the isoform B.
• the G-CSF is a human G-CSF or an engineered variant thereof.
• the preferred human G-CSF sequences include natural isoforms of G-CSF, in a preferred embodiment the isoform of G-CSF is isoform B, more preferably secreted form of the isoform B.
• the preferred G- CSF comprises the sequence of the secreted form of human G-CSF isoform B, also known as lenograstim sequence, sequence ID NO: 4.
• the preferred forms includes of filgrastim comprising an additional N-terminal methionine (SEQ ID NO:1 ). It is realized that G-CSF forms or derivatives with larger molecular weight are especially useful forms of G-CSF, preferred G-CSF peptide derivative forms include:
• glycosylated form of the cytokine preferably CSF, preferably human G-CSF
• glycosylated form of the secreted human G-CSF isoform B (lenograstim)
• mammalian type O-glycosylation preferably mammalian type glycosylation produced in chines hamster ovary cells (CHO cells) as in the commercial G-CSF.
• Bioactivity studies of G-CSF, especially lenograstim has been described e.g. by Houston A.C et al Br. J. Pharmacol., 1999, 47, 279.
• the pegylated form of the cytokine preferably CSF, preferably G- CSF, such as pegylated filgrastim sequence or pegylated lenograstim sequence, or pegylated glycosylated lenograstim, or a human G-CSF such as lenograstim of filgrastim sequence pegylated to glycans (glycopegylated).
• the preferred G-CSF may be pegylated to N-terminus, preferably being pegylated filgrastim such as pegfrilgrastim (NeulastaTM) or to glycans such as glyco- pegylated products of Biogenerix (WO2009/027437).
• the invention is further directed to multiply protein and/or glycan pegylated forms of the preferred cytokine, preferably G-CSF, such as multiply pegylated filgrastim (WO2010/051335).
• cytokine preferably G- CSF
• G-CSF preferably designed to increase serum half-life of the G-CSF
• human albumin-G-CSF fusion protein WO2010/083439
• the invention is directed to uses, methods, compositions, dosage forms of the invention wherein the G-CSF is a hu- man G-CSF, preferably glycosylated, pegylated or pegylated and glycosylated, lenograstim or filgrastim peptide containing G-CSF or a fusion protein derivative thereof.
• G-CSF is a hu- man G-CSF, preferably glycosylated, pegylated or pegylated and glycosylated, lenograstim or filgrastim peptide containing G-CSF or a fusion protein derivative thereof.
• human G-CSF is other than pegfil- grastim (NeulastaTM) selected from the group: a G-CSF wherein the peptide sequence consist of lenograstim peptide sequence or its pegylation and/or gly- cosylation derivative, filgrastim (commercial non-glycosylated form), or optimized multiply pegylated filgrastim (WO 2010/051335).
• NelastaTM pegfil- grastim
• the human G-CSF is a glycosylated, or pegylated and glycosylated, or multiply pegylated lenograstim (secreted human G-CSF isoform B) or filgrastim sequence (secreted human G-CSF isoform B including additional N-terminal methionine) containing G-CSF.
• a cytokine which has substantially same activity as above where, in the amino acid sequences constituting the above-mentioned cytokines, one or several amino ac- id(s) is/are deleted or substituted or some additional amino acids are added.
• the term "deleted or substituted or some additional amino acids are added” means that, in any position of the same sequence, there is deletion, substitution or addition of one or more amino acid residue(s). Deletion, substitution or addition as such may take place at the same time and the amino acid residue (s) which is/are deleted, substituted or added may be either a natural type or a non-natural type.
• the person skilled in the art is aware of the amino acid residues which can be substituted by each other, for example, amino acid residues belonging to the same group can substitute each other.
• Hyaluronan oligomers and/or polymers are unbranched polysaccharides that consist of repeating disaccharide units.
• Hyaluronic acid is composed of D-glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) linked together via alternating ⁇ -1 ,4 and ⁇ -1 ,3 glycosidic bonds.
• Hyaluronic acid can be 25 000 disaccharide repeats in length.
• Polymers of hyaluronic acid can range in size from 5 000 to 20 000 000 Da in vivo.
• Hyaluronic acid is naturally non-sulphated.
• the present invention is directed to novel low molecular weight fragments of hyaluronic acid (LMW HA) including polymers and/or oligomers or mixtures thereof having molecular weights less than about 25 000 Da, preferably less than 15 000 Da, more preferably less than 10 000.
• LMW HAmer is a HAmer or a mixture of HAmers having molecular weight on average about 5000 Da or less.
• the structure of the hyaluronic acid oligomer and/or polymer of the present invention is described in Formula
• Ri is non-reducing group, which is GIcA or its beta-elimination product containing a double bond between 4- and 5-position of the uronic acid ring (delta-hexuroronic acid);
• R 2 and R 3 are independently either H or acetyl or 3-10 C-alkyl or al- kanoyl derivative of the amine or sulphate amide, the R 3 may also vary at each position of the chain;
• R is a reducing end group, which is GIcA or its reducing end derivative including preferably reducing (aldehyde containing) and non-reducing (aldehyde derivative) reducing end structures;
• n1 and n3 are integers being either 0 or 1 ,
• n2 is an integer varying from 2-50, preferably 4-25,
• the reducing end GlcN may be derivatized as described for R 4 ;
• the GlcN residue may be further derivatized by sulphate residue at position 2 and/or 4 and/or 6, more preferably to 6-position, and GIcA residue(s) may be optionally derivatized by sulphate residue at position 2 and/or 3.
• hyaluronic acid oligomer and/or polymer of the invention is described in Formula II described below:
• n1 , n3 and n4 are integers 0 or 1 , defining the presence or absence of the specific structures;
• W is a linking atom (group) selected from group C, C(O), C(H2), N, N(H), or S, or nothing, optionally replacing reducing end/C1 -linked oxygen of R4 or hydroxyl of R5;
• Y is nothing, reducing end deri- vatization group selected from group, hydrogen, sulphate ester, an alkyl, a substituted alkyl, carboxylic acid, aryl, heteroalkyl, cycloalkyl, heteroaryl, or two of these in case W is N, or three in case W is carbon;
• R4 is a monosaccharide or derivative,
• R5 is a monosaccharide or derivative;
• R6 is, primary hydroxyl or its sulphate ester, and it may vary in each position of the HAmer.
• the HAmer is a mixture of 6-sulphated, and optionally further reducing end O-sulphate ester structures, and in another embodiment further N-sulfate derivatives of non-acetylated/non-acylated GlcN residues, and further optionally sulphate esters on the other hydroxyl-groups, preferably as defined for Formulas.
• the sulpahated HAmer molecules comprise at least one sulphated HAmer backbone structure.
• the sulphated HAmer is a mixture of sulphated HAmer molecules having desired average sulphation, prefer- ably being 6-sulphation (R6 sulphate ester) levels of the invention.
• the preferred mixtures of desired sulphation level comprises in specific embodiment at least 5 %, or 10 %, or 20 %, or 25 % or 30 %, or 35 % or 40 % or 45 % or 50 % or 60 % of HAmer comprising single sulphate ester per molecule, in an em- bodiment being 6-sulphate or mostly (50 % or 75 % or 90 %) 6-sulphate.
• the group Y comprises in an embodiment at least 1 -24 carbon, in another embodiment 1 -10 carbon, in a further embodiment 1 -6 carbon atoms.
• W is N(H) modified by Y groups being carboxylic C 2- 6 carboxylic acids such acetic acid, propionic acid, butyric acid or caproic acid.
• the group Y also a similar small organic molecule and it may be further substituted other chemical structures.
• the invention is directed to the molecules comprising non-reducing (non-aldehyde) structure as the reducing end monosac- charide residue position, preferably R4 is lower (second row middle) the open chain C1 - reduced GIcA residue its derivative by W-Y, or R5 is (the second row on left) anhydromannitol structure or its derivative by W-Y, or (3 rd row on right) reduced GlcNR3 or its derivative wherein C1 OH is replaced by W-Y or when R4 or R5 is derivatized by on organic residue Y-W (other than nothing or hy- drogen (H).
• R4 is lower (second row middle) the open chain C1 - reduced GIcA residue its derivative by W-Y
• R5 is (the second row on left) anhydromannitol structure or its derivative by W-Y, or (3 rd row on right) reduced GlcNR3 or its derivative wherein C1 OH is replaced by W-Y or when R
• the HAmer is selected from the following group:
• Glycolipid and carbohydrate nomenclature is essentially according to recom ⁇ mendations by the lUPAC-IUB Commission on Biochemical Nomenclature (e.g. Carbohydrate Res. 1998, 312, 167; Carbohydrate Res. 1997, 297, 1 ; Eur. J. Biochem. 1998, 257, 29).
• GlcNAc N- acetylglucosamine
• GlcN gluccosamine
• GIcA glucuronic acid
• glycan means here broadly oligosaccharide or polysaccharide chains present in human or animal glycoconjugates, especially on gly- colipids or glycoproteins.
• the carbohydrates can be synthesized by enzymatic, and/or chemical methods, from commercial and known raw materials, there is extensive literature of glycan synthesis by organic synthesis (Carbobohydrates in Chemistry and Biology parts l-ll (volumes 1 -4), 2000, Eds. Ernst B., Hart, G.W., and Sinay P.
• hyaluronic acid backbones can be produced by enzymatic synthesis by recombinant enzymes (DeAngelis, Oklahoma, and company Hy- alose and Novozymes, Denmark) or bacterial fermentation, or isolation from rooster combs or other biological sources. Synthesis enzymes has been reviewed in Weigel PH, and DeAngelis PL., J Biol Chem. 2007 282(51 ):36777- 81 . Organic synthesis and further analogs and derivative production is described in Halkes KM et al Carbohydr Res. 1998 Jun;309(2):161 -74. Reference for commercial therapeutic grade large Mw hyaluronic acid, Sup GmbH (TM), use- ful for degradative production of HAmer structures Curran MP Drugs Aging. 2010 Nov 1 ;27(1 1 ):925-41 .
• Glycan epitope or epitopes means oligosaccharide sequence and elongated epitope means reducing end elongated preferred oligosaccharide sequence variants.
• saccharide sequence means specific sequence of glycosidically linked monosaccharide residues, including terminal and “core” sequences.
• expression “terminal saccharide sequence” indicates that the oligosaccharide is not substituted to the non-reducing end terminal residue by another monosaccharide residue or residues.
• the non-reducing end of the sac- charide sequence consist of the poly- or oligosaccharide sequence and it is only modified from the reducing end of the oligosaccharide sequence, preferably it is glycosidically conjugated from the reducing end.
• the invention is directed to saccharide sequences and optimization thereof, when reducing end structures W-Y are varied.
• carbohydrate chain of the molecule forms an active part of the molecule and the invention is further directed optimization of the structure by producing and testing a library of the derivative of molecules of the Formulas of the invention, especially derivative in position of Y.
• LMW HAmer refers to a HAmer and/or a mixture of HAmers comprising from 2 to 100, preferably from from 2 to 50, and more preferably from 4 to 25 dimer-units.
• Sulphated low molecular weight hyaluronic acid refers to a hyaluronic acid oligomer and/or polymer or as mixture thereof comprising from 2 to 100, preferably from 2 to 50, and more preferably from 4 to 25 dimer-units that are sulphated i.e., carry a sulphate-group attached to the N- acetylglucosamine or optionally also glucosamine-unit of the dimer.
• the sul- phation level of the HAmer of the present invention is from about 0.1 to about 1 .5.
• the average sulphation level is between about 0.15 to about 1 .0 sulphate residues per a dimer.
• the sul- phate group is preferably esterified to 6 positions of GlcNR- residues.
• the preferred active 6-sulphated hyaluronic acid may further comprise partially de-N- acetylated structures, which may be N-sulphated or glucosamine (GlcN)- residues without amine sulphation.
• the amount of GlcN and/or N-sulpahated GlcN residues is less than about 20% of the GlcNR resi- dues, preferably the amount of GlcN with amine fuction, is between 0.1 -20 %, more preferably between 0.2-20 % or most preferably between 1 and 15 %. In a specific embodiment at least 5 % of the GlcN-residues are N-sulphated. The amine function or its sulphated derivative are favoured for chemical production and/or modulation of bioactivity.
• the HAmers are preferably specifically 6-sulphated so that at least
• sulphate is linked to the 6-position of GlcN(Ac).
• Preferred 6-sulphation levels are from about 0.1 to about 1 .0, more preferably from about 0.15 to about 1 .0 sulphate residues per a dimer.
• the sulphation level is medium level preferably from about 0.20 to about 0.9 sulphate residues, more prefera- bly from about 0.25 to about 0.80 sulphate residues per a dimer of the glycan backbone.
• the number of glycan backbone dimers is defined by variable n2 of Formula I.
• the invention is directed to essen- tially non-sulphated HAmers of Formula I, preferably comprising less than 0.2 sulphate residues per dimer defined by n2 of Formula I, more preferably less than 0.1 sulphate residues, and in a specific embodiment less than 0.03 sulphate residues.
• specific sulphated forms, especially 6-sulphate forms are favoured for chemical production and/or modulation of bi- oactivity.
• the HAmer of the present invention comprise non-reducing end Ri (GlcA or derivative, n1 of Formula I is 1 ) and further preferably reducing end GlcNR 3 (n3 of Formula I is 0).
• at least 60 %, more preferably at least 70 %, even more preferably at least 80 %, even more preferably at least 90 % , and most preferably at least 95 % of the non-reducing end residues are GlcA and/or at least 60 %, more preferably at least 70 %, even more preferably at least 80 %, even more preferably at least 90 % , and most preferably at least 95 % of the reducing end residues are GlcN .
• the levels of the non-reducing end GlcA and re- ducing end GlcN are essentially similar (at least about 60, 70, 80, 90, or 95 %).
• the reducing and non-reducing end structures are favoured for effective chemical synthesis and benefits in bioactivity, uniformity and standardization of the therapeutic substances.
• the present invention is based on a surprising finding that a sulphated HAmer can be used to enhance and/or improve the effect of a factor capable of mobilizing stem cells in releasing the stem cells from their place of origin, typically from the bone marrow, into the blood circulation.
• the object of the present invention is to provide a combination or a combined use of a sulphated HAmer and a factor capable of mobiliz- ing stem cells.
• a sulphated HAmer suits to be used in combination with a factor mobilizing stem cells to mobilize and/or release stem cells to the bloodstream for collection and subsequent transplantation in patients suffering from cancers, such as leukemias, lymphomas and myelomas.
• a sulphated HAmer in combination with at least one factor capable of mobilizing stem cells provides an enhancement for the treatment of cancers that require a stem cell transplant.
• the therapeutic indications for the combination and/or combined use of a sulphated HAmer and at least one factor capable of mobilizing stem cells include mobilization of stem cells for autologous and/or allogenic transplants and tumor sensitization in oncological and hematological maladies.
• the HAmers are suited for treating condi- tions requiring immunomodulation, such as, therapeutic immunomodulation in context of cancer treatments, or for preventing side effects of blood cell donation and/or blood cell count or content modulation e.g. by growth factors such as G-CSF.
• the amount or content of the factor mobilizing stem cells can be reduced and/or lowered, the number of stem cells in peripheral blood is increased, and/or the number of apheresis sessions or the duration of the sessions for harvesting the minimum number of cells (approximately 2 million stem cells/kg of body weight) can be reduced.
• the combination or combined use of at least one sulphated HAmer and at least one factor capable of mobilizing stem cells is more efficient than a factor mobilizing stem cells alone in mobilizing and collecting the optimal number of stem cells for transplantations.
• the advancements and advantages the combination or combined use of the present invention provides for the treatment of certain malignant diseases and cancers requiring stem cell transplantation include more rapid collections of stem cells, larger numbers of stem cells and faster recovery times.
• the combination is used to alter or modulate the relative amounts of blood cells and/or the types of blood cells or the HAmer and the factor mobilizing stem cells are used in combination to alter or modulate the relative amounts of blood cells and/or the types of blood cells.
• the combination is used for repairing or improving the blood count of a subject or the HAmer and the factor mobilizing stem cells are used in combination for repairing or improving the blood count of a subject.
• the combination is used to mobilize stem cells to the bloodstream of the subject, typically from the bone marrow or the HAmer and the factor mobilizing stem cells are used in combination to mobilize stem cells to the bloodstream of the subject, typically from the bone marrow.
• a sul- phated HAmer and a factor capable of mobilizing stem cells, such as G-CSF in its pegylated form (NeulastaTM) and plerixafor have shown an unexpected positive co-operative action.
• Pegylated C-GSF is known to have good activity in avoiding graft versus host disease, and the combination and/or combined use of the invention showed enhanced immunomodulatory effects.
• the sulphated HAmer is a low moleculer weight sulphated HAmer.
• the factor capable of mobilizing stem cells is G-CSF and/or its therapeutically suitable and/or pharmaceutically acceptable derivates, conjugates and analogs, such as, pegylated G-CSF.
• the factor capable of mobilizing stem cells is plerixafor, optionally in the form of a pharmaceutically acceptable salt such as a sodium salt.
• Perlixafor and analogous CXCR4 inhibitors have been used to mobilize stem cells in combination particular growth G-CSF filgrastim.
• the present invention revealed that the effect of a derivatized cytokine (growth factor) or CSF-factor, such as a pegylated filgrastim including pegfilgrastim is even more effectively increased than the effect filgrastim by combination with per- lixafor.
• Perlixafor Mozobil, trade mark
• the present invention revealed that the novel sulfated HAmer products releases stem cells with similar effect in combination with a cytokine as filgrastim. It is further realized that present HAmer molecules are highly water soluble and have different biodistribution profile than perlixafor type agents with a broader distribution range of activities and interactions. It is realized that high dose range and neglible side effect observable are a benefit of the present combination.
• the use may optionally include harvesting the mobilized cells from the bloodstream, culturing said harvested cells and/or administering said harvested cells to a recipient subject.
• the method may optionally include harvesting the mobilized cells from the bloodstream, culturing said harvested cells and/or administering said harvested cells to a recipient subject.
• the donor subject and the recipient subject may be the same person.lt is also an object of the present invention to provide a method for altering the relative amounts of blood cells and/or the types of blood cells of a subject by administering a sulphated HAmer and a factor capable of mobilizing stem cells or the combination thereof to said subject.
• the present invention relates to a method of altering the relative amounts of blood cells and/or the types of blood cells. In another embodiment, the present invention relates to a method for repairing the blood count of a subject by administering a sulphated HAmer and a factor capable of mobilizing stem cells or the combination thereof to said subject. In a further embodiment, the present invention relates to a method of mobilizing stem cells to the bloodstream by administering a sulphated HAmer and a factor capable of mobilizing stem cells or a combination thereof to said subject. In one preferred embodiment, the factor capable of mobilizing stem cells is G-CSF.
• the present invention is based on a surprising finding that a non-sulphated and/or a sulphated HAmer can be used for altering the relative amounts or numbers of different blood cells and/or the types of blood cells such as white blood cells, red blood cells and platelets.
• White blood cells or leucocytes can be diveded into granulocytes (polymorphonuclear leukocytes) and agranulocytes (mononuclear leucocytes).
• Granulocytes can be further divided into neutrophils, basophils and easinophils.
• Agranulocytes include lymphocytes, monocytes and macrophages.
• the relative amounts or numbers of different blood cells and/or the types of blood cells differ in and/or are indicative to certain hematological and/or oncological diseases or emergencies.
• the HAmers are suited for treating conditions requiring im- munomodulation, such as, therapeutic immunomodulation in context of cancer treatments, or for preventing side effects of blood cell donation and/or blood count or blood cell content modulation e.g. by growth factors such as G-CSF.
• im- munomodulation such as, therapeutic immunomodulation in context of cancer treatments
• growth factors such as G-CSF.
• the object of the present invention to provide use of a non-sulphated and/or a sulphated HAmer for altering the relative amounts of blood cells and/or the types of blood cells in a subject.
• Another object of the present invention is to provide use of a non- sulphated and/or a sulphated HAmer for repairing the blood count of a subject.
• the sulphated HAmer When used in combination with a factor ca- pable of mobilizing stem cells, it can be administered to a subject together with or separately from the administration of the factor mobilizing stem cells. When administered separately from the factor capable of mobilizing stem cells, the sulphated HAmer can be administered before, simultaneously or after the administration of the factor capable of mobilizing stem cells.
• the HAmer and/or the factor mobilizing stem cells can be formulated to a pharmaceutical composition.
• the combination of at least one sulphated HAmer and at least one factor mobilizing stem cells can be formulated for example to a single dosage form preparation or a kit-type preparation depending on the mode of administration.
• the phar- maceutical composition in a single dosage form preparation or a kit-type preparation comprises at least one HAmer and in another embodiment, at least one HAmer and at least one factor capable of mobilizing stem cells.
• HAmer is formulated in a first formulation and the factor mobilizing stem cells is formulated in a second formulation, and the first and the second formulations are administered simultaneously or sequentially, in any order, to a subject.
• HAmer is administered prior to administration of the factor mobilizing stem cells.
• the factor mobilizing stem cells is administered prior to administration of the HAmer.
• the time period between the administration of the HAmer and the fac- tor mobilizing stem cells varies and depends on the condition to be treated.
• the pharmaceutical compositions may be used parenterally or en- terally for example in liquid, semisolid or solid form such as in the form of a solution, an emulsion, a suspension, a tablet, a pellet or a capsule.
• the pharmaceutical composition is in a liquid form, such as an infu- sion solution, to be administered to blood circulation.
• the invention is especially directed to human acceptable infusion components including optionally physiological salts and/or nutrients.
• the infusion comprises cytokines or factors capable of mobilizing stem cells
• the infusion is formulated in order to keep the combination of the molecules soluble for effective infusion.
• the pharmaceutical composition may comprise pharmaceutically acceptable carrier(s), adjuvant(s), excipient(s), stabilizing, thickening or colouring agent(s), binding agent(s), filling agent(s), lubricating agent(s), suspending agent(s), sweetener(s), flavouring agent(s), gelatinize ⁇ ), anti-oxidant(s), preservative(s), pH regulator(s), wetting agent(s) or components normally found in corresponding products
• composition of the invention comprises the HAmer of the invention and/or at least one factor capable of mobilizing stem cells in an amount sufficient to produce the desired effect.
• Other ingredients as well as other specific components of the pharmaceutical compositions may either be obtained commercially or prepared by conventional techniques known in the art.
• the compositions may be manufactured by any conventional processes known in the art.
• Typical indications for allogeneic transplantation are leukemi- as. Healthy cell donors for allogeneic hematopoietic cell transplantion can be treated with various doses, typically 2 - 40 micrograms/kg of G-CSF to mobilize the CD34 positive cells from bone marrow to the peripheral blood.
• the mobilized cell fraction is collected using apheresis (leukopheresis) and the cells can be infused into the patient.
• the number of CD34 cells increases about 20-fold within a few days of the administration of the growth factor, followed by a decline in about 1 week.
• the treatment is regarded generally as safe, but a high proportion of donors, about a half, however suffer from ad- verse events.
• the only factor known to be related to poor mobi- lizer status is high age.
• the chemotherapy that is applied to reduce the number of malignant cells in the patient, results also in a transient reduction in the number of hematopoietic cells in the periph- eral blood. To keep the homeostasis this is rapidly corrected by mobilization of stem cells from the bone marrow.
• growth factors such as G-CSF
• the number of mobilized stem cells can be increased up to 100-300 fold.
• the cells can be collected by apheresis and are stored usually as an enriched mononuclear cell fraction, until infused back into the patient.
• Typical indications for autologous transplantation are lymphomas, mye- loma and chronic lymphoid leukemia.
• additional indications for the present invention include neutropenic patients who have a history of severe infections or who are infected by human immunodeficiency virus (HIV).
• the present invention provides a method of treating or preventing neutropenia in a subject comprising administering to said subject the HAmer of the invention and/or at least one factor capable of mobilizing stem cells in an amount sufficient to produce the desired effect.
• the present invention relates to a use of the HAmer of the invention and/or at least one factor capable of mobilizing stem cells in the treatment of neutropenia and/or in the manufacture of a medicament for the treatment of neutropenia.
• the invention is further directed to method of analyzing the HAmer activity in an animal test and methods of administering the HAmer into animal and measuring the amount of stem cell and blood cells.
• the invention is especially directed to animal models for clinical trial including mammalian models mice and rodent, larger mammals such as dogs or ferret, and a non-human primate clinical model such as rhesus monkey or a chimpanzee.
• the invention is further directed to the use of present molecules for development of analogs of the molecules, or validation of bioactive molecules, by methods including comparing biologic activity of the present molecule to other molecules with stem cell mobilization and/or blood cell composition/count altering activities.
• the invention is also directed to preparations comprising isolated cell populations derived from harvested cells produced by a mammalian subject by using the present methods, composition, combinations, uses and any other aspect of the present invention.
• the preparations and/or cell populations are characterized by presence of the HAmer products, especially sulphated HAmer, and optionally further an agent capable of immobilizing stem cells, preferably at least one cytokine, more preferably a human G-CSF, including equivalent human therapeutic C-CSFs.
• the cell populations have clear benefit because 1 ) the populations are larger than produced by e.g. individual growth factors, cytokines or CSF- products, as a therapeutic cell population is in general pro- prised by single subject (donor/patient), 2) the novel cell populations have useful properties before harvesting supporting better the blood functions of the person subjected to the mobilization of stem cells such as useful profile of erythrocytes and leukocytes, 3) the novel sulphated HAmer products do not in- volve the biological profile of other mobilizing agents, and the side effects of the products are minimal and currently not observed even with relatively high doses.
• the combination therapies that present products, uses and methods, especially the one comprising sulphated HAmer, can be used to reduce the amount of a cytokine or other mobilizing agent with potential side effects.
• the invention also is directed to the methods of analysing the HAmer from the isolated cell population.
• the novel therapeutic cell populations of the invention such as described in example 13, can be used in the treatment of neutropenia and the incidence of febrile neutropenia in pa- tients treated with cytotoxic chemotherapy for malignancy, and for enhancing mobilization of hematopoetic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma.
• mice in Example 12 An effective dose of sulphated HAmer according to the invention for mobilizing cells was determined in mice in Example 12 as 20 mg/kg given intravenously. At two times higher dose, 40 mg/kg, the effect appeared preliminarily not be substantially increased, indicating that 20 mg/kg is a preferred effective dose in mice. At both doses, no adverse effects were observed, indicating safety at these dose levels. Conversion of these doses from mice to hu- man use is done using the body surface area (BSA) normalization method (Reagan-Shaw et al. 2007, FASEB J. 22, 659-661 ; Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research, 2002. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, U.S. Food and Drug Administration, Rockville, Maryland, USA), yield- ing doses of 1 .6 mg/kg and 3.2 mg/kg, respectively, for the two effective or clinical trial starting doses in humans according to the invention.
• BSA body surface area
• effective dose range is between 0.016 mg/kg and 320 mg/kg, more preferably between 0.08 mg/kg and 64 mg/kg, more preferably between 0.16 mg/kg and 32 mg/kg, more preferably between 0.32 mg/kg and 16 mg/kg, more preferably between 0.6 mg/kg and 8 mg/kg, and even more preferably between 1 mg/kg and 4 mg/kg.
• the dose range is between 0.5 mg/kg and 10 mg/kg, or 1 .0 mg/kg and 10 mg/kg,
• an effective and safe dose for a particular patient may depend on a number of factors, including the specific disease indication, severity of the disease, gender, age, condition and/or health of the patient, dosing schedule, administration route, and other medications used on the patient. It is further realized that an effective and safe dose range may be determined in human subjects based on clinical response and safety measurements to determine maximum tolerated dose and minimum effective dose, op- tionally for each patient group, according to standard clinical trial procedures and for example a dose escalation study.
• sulphated HAmer may be used in higher amounts, such as 3 mg/kg to 250 mg/kg or about 5 mg/kg to about 100 mg /kg either a single substance to obtain maximal effect on blood count, or in combination with other agents such as CSFs and/or other stem cell mobilizing agent to re- prise the amounts and possible side effects of the additional treatments or molecules.
• effective dose range is between 0.016 mg/kg and maximum tolerated dose, more preferably between 0.08 mg/kg and maximum tolerated dose under, more preferably between 0.16 mg/kg and maximum tolerated dose, more preferably between 0.32 mg/kg and maximum tolerated dose, more preferably between 0.6 mg/kg and maximum tolerated dose, and even more preferably between 1 mg/kg and maximum tolerated dose.
• effective dose range is between minimum effective dose and maximum tolerated dose.
• effective dose is the maximum tolerated dose.
• mobilizing sulphated HAmer according to the invention is used in a human patient or subject being treated with another agent selected from the group, of G-CSF, GM-CSF another cytokine or their derivatives such as pegylated derivatives or plerixafor,.
• another agent selected from the group, of G-CSF, GM-CSF another cytokine or their derivatives such as pegylated derivatives or plerixafor.
• sulphated HAmer or HAmer of the invention is used in a patient being treated with a growth factor, for example G-CSF or GM-CS.
• a growth factor for example G-CSF or GM-CS.
• sulphated HAmer or HAmer is used in a patient being treated with preffered G- CSF such as filgrastim or lenograstim, or glycosylated or glycopegylated or multiply-pegylated derivative thereof a as stem cell, especially CD34+ hema- topoietic stem cell, mobilizing agent.
• mice were used in the in vivo mobilization experiments. The acclimatization period was always at least 7 days before the experiments. The animals were individually identified by ear and tail numbering and were housed in a Scantainer (Scanbur A S, Karlslunde, Denmark) in Makrolon III cages. The animal room temperature was 21 ⁇ 2°C and humidity was between 40-60%. Lightning was artificial, 12 h light and 12 h dark. The mice were provided with irradiated fodder and normal tap water ad libitum. Average weight of all animals in the experiments was 18.8+1 .5 g. No formal randomization or grouping was done. Animals were randomly allocated to the study groups. All animals were weighed before the first dosing and in the end of each study.
• Sterile filtered PBS (pH 7.2) served as vehicle in all studies and was injected intravenously in the tail vein in similar volumes (50 or 100 ⁇ ) and time- points as the other test items within each study.
• the animals obtained 25 ⁇ g pegfilgrastim (NeulastaTM) subcutaneously at a dose volume of 50 or 100 ⁇ on study day 0.
• the LMW hyaluronic acid derivatives HA and 6-O-S HA were prepared for injections into sterile filtered PBS in 5-10 mg/ml solutions and injected intravenously in the tail vein in dose volumes of 50 or 100 ⁇ yielding 500 ⁇ g doses/mouse.
• the LMW hyaluronic acid (HA) derivatives were tested for capability to mobilize hematopoietic stem and progenitor cells to peripheral blood after 500 ⁇ g i.v. injections at the following time-points: 4h, 1 d, 2d, 3d and 5d post- injections. Repetitive dosing was tested with daily 500 ⁇ g i.v. injections and sampling was done either on experimental days 2 (after 3 doses) or 5 (after 6 doses) after the first injection on day 0. Abnormal clinical signs or mortality was not observed with the LMW HA derivatives with 500 ⁇ g doses.
• the LMW HA derivatives were also tested in combination with a single dose of pegfilgrastim (NeulastaTM). In combinatorial G-CSF + LMW HA studies, pegfilgrastim was always injected s.c. at experimental day 0 and the LMW HA derivatives were administered i.v. as
• the vehicle groups were always injected with 0.9% NaCI by similar routes, volumes and time-points as the experimental groups. Sampling and sample handling
• the leukocyte, erythrocyte and platelet contents were determined for all blood samples by automated blood cell counter Sysmex XT-2000i by diluting the mouse blood 1 :4 with 0.9% NaCI.
• Paque ® (GE Healthcare) with peripheral blood diluted 1 : 2 in phosphate buffered saline (PBS)-2mM EDTA. Tubes were centrifuged for 40 minutes at 400 x g without brake. The mononuclear cell layer at the interphase was collected and washed twice in PBS-2mM EDTA. Tubes were centrifuged for 10 minutes at 300 x g. Mononuclear cell yields were counted using a Burker chamber.
• PBS phosphate buffered saline
• Bone marrow was isolated from femurs by making small incisions with scalpels and flushing out the marrow with 21 G needle using Iscoves' MDM media (invitrogen) supplemented with 2% FCS (!nvitrogen). Flow cytometry
• Flow cytometric analysis was performed on FACSAria (Becton Dickinson Biosciences) with a 488-nm argon laser for (PE, FITC and PE-Cy7), a 633-nm hene laser for (APC and APC-Cy7). Fluorescense was measured using 530/30-nm (FITC), 585/42-nm (PE), 780/60-nm (PE-Cy7), 660/20-nm (APC) and 780/60 (APC-Cy7) bandpass filters. Data visualization utilizing bi- exponential displays were analysed by FACSDiva software (BD Biociences).
• Hematopoietic cell populations of mouse peripheral blood by flow cytometric analysis Hematopoietic cell populations of mouse peripheral blood by flow cytometric analysis.
• Peripheral mouse blood was diluted 1 :5 in 0.9% NaCI (Baxter).
• Fluorescence labels ebiosciences, except APC-CD45 BD Biosciences: 0.04 ⁇ g phycoerythrin (PE)-conjugated CD1 1 c (dendritic cells; clone N418;cat#12- 01 14), fluorescein isothiocyanate (FITC)-conjugated 0.3 ⁇ g TER-1 19 (erythroid cells; clone TER-1 19; cat#1 1 -5921 ), 0.1 ⁇ g allophycocyanin (APC)-conjugated CD314 (natural killer cells; clone CX5;17-5882), 0.08 ⁇ g APC-Cyanine 7 (Cy7)-conjugated CD3e (T cells; clone 17A2; cat#27.0032) and 0.04 ⁇ g PE- Cy7 conjugated CD45R (B cells; RA3-6
• the fluorescence labels were selected according to brightness and minimal potential spectral overlap. The brightest fluorochrome was given to the 'dim' antibodies and vice versa. Antibodies in each cocktail were selected to best differentiate between closely related cell populations. To validate multicolour reagent panel and avoid minimal compromising of the readout, both fidelity controls and fluorescence-minus-one controls were used. These controls were also used to check the gating of the detected cell population. CompBeads Compensation Particles anti-rat/hamster IgGK were used to compensate the fluorescence (BD biosciences). Each tandem-label with different lot# was compensated separately, unity of the tandem-label confirmed and the proper compensation of the automated calculations controlled manually.
• monocyte-neutrophil-eosinophil (MNE) populations were gated from the CD45+ cells with high side scatter, thus not including lymphocytes. Hematopoietic progenitors in the lymphoid cell population expressing CD1 15 or CD41 were also calculated.
• the proportions of T cells, B cells, NK cells, proerythroblasts and dendritic cells were analyzed by first gat- ing the lymphocyte population and detecting the fluorescence labelling of the adequate marker.
• CD314+ cells had to be negative for CD3e to be considered NK cells.
• Immature dendritic cells were CD1 1 c+ but negative for T and B cell markers CD3e and CD45R, respectively.
• LTR long-term repopulating hematopoietic stem cells
• APC-CD45 catalog number 559864; BD Pharmingen
• PE-CD150 catalog number 12-1501 -82; eBiosciences
• FITC-CD48 catalog# 557484; BD Pharmingen
• CD45+ cells expressing CD150, but not CD48 cell surface markers were determined as a population highly enriched with LTR hematopoietic stem cells.
• CFU Hematopoietic progentitor cell assay
• Myeloid hematopoietic progenitor cells were further enumerated by the colony forming unit (CFU/CFC) assay.
• Progenitor cells that are restricted in their lineage potential and that have limited self-renewal capability can be detected in colony-forming cell (CFC) assays using semisolid media such as methylcellulose, agar or collagen.
• Progenitors that read out in culture assays can either be multipotent, e.g. capable of generating progeny of multiple blood cell types, or restricted to one or two lineages, e.g. erythrocytes, granulocytes, monocyte/macrophages or platelets.
• This culture system supports the proliferation and differentiation of individual progenitor cells, termed colony- forming cells (CFCs), into discrete colonies containing recognizable progeny. CFCs are classified and enumerated based on morphologic recognition of mature cells within the colony.
• CFCs colony- forming cells
• MethoCult® M3434 "Complete Medium with Cytokines" (Stem Cell Technologies) containing 1 % Methylcellulose, 15% Fetal Bovine Serum, 1 % Bovine Serum Albumin, 10 ⁇ g ml insulin, 200 ⁇ g ml transferrin, 50 ng/ml recombinant SCF, 10 ng/ml recombinant IL-3, 10 ng/ml IL-6 and 3 U/ml recombinant EPO in Iscoves' MDM media (Invitrogen) was used according to the manufacturer's instructions with 1 x10 5 mononuclear cells isolated by Ficoll density centrifugation.
• CFU-GEMM granulocyte-erythrocyte-macrophage-megakaryocyte colony-forming cells
• CFU-GM granulocyte-macrophage colony-forming cells
• BFU-E burst- forming unit-erythroid
• CFU-E colony-forming unit-erythroid
• Results are expressed as average +SD except for the cell counts presented as scatter dot plots with means +SEM. Statistical differences were determined by either two-tailed unpaired t test or one-way analysis of variance with Bonferroni's Multiple Comparison post test. Values of p ⁇ 0.05 were considered to be statistically significant. GraphPad Prism 5 was used for statistical analysis. EXAMPLE 1
• G-CSF dose mobilization of HPC to blood, HPC contents in bone marrow and G-CSF-induced spleen swelling
• HPC circulating hematopoietic progenitor cells
• HPCs in the bone marrow were determined by CFU assay in which 1 x10 5 mononuclear cells isolated from both peripheral blood and bone marrow were used.
• the mice were treated with a single dose of 25 ⁇ g pegfilgrastim s.c. at day 0 and the samples were collected at day 5.
• the number of circulating HPCs in mouse peripheral blood increased 40-50- fold over background with the dose and time-point used.
• the number of HPCs in the bone marrow decreased over 2-fold.
• the used pegfilgrastim dose did not leave the bone-marrow entirely devoid of HPCs, since there were still a higher number of HPCs left in the bone marrow/1 x10 5 bone marrow mononuclear cells than there were mobilized HPCc present in the blood after the G-CSF stimulation ( Figure 1 ).
• the levels of HPCs in untreated (vehicle) mice bone marrow were substantially higher than the HPC levels in the similar amount of mononuclear cells isolated from pegfilgrastim-mobilized peripheral blood ( Figure 1 ).
• the efficiency of 25 ⁇ g pegfilgrastim to mobilize HPCs was concluded to peak at 5 days after the s.c. injections as shown in Figure 9A. Spleen swelling was evident already two days after the s.c. injection and, in line with the number of mobilized HPCs, also peaked 5 days after the injection ( Figures 8A and 8B).
• LMW hyaluronic acid oligosaccharide derivatives induce alterations in peripheral blood cell profile
• the white blood cell (WBC) contents in peripheral blood were studied after single dose administrations of 500 ⁇ g LMW hyaluronic acid derivatives HA and 6-O-S HA at different time-points and compared to WBC levels in the vehicle and pegfilgrastim (NeulastaTM) groups.
• the LMW hyaluronic acid derivatives caused a rapid elevation in the numbers of circulating WBC 4 hours after i.v. injections and the levels were comparable to those caused by pegfilgrastim.
• the LMW 6-O-S HA caused an elevation in the WBC contents, especially 3 days after the i.v.
• red blood cell (RBC) and platelet (PLT) contents in peripheral blood were also studied in the same samples as was used for WBC determination. As presented in Figures 4 and 5, no evident changes in RBC levels were detectable after administration of the LMW HA derivatives. Pegfilgrastim was found to elevate the numbers of mature RBC 2-5 days after the s.c. injections ( Figures 4B and Figures 5A and 5B), but the RBC elevation was also occasionally seen to normalize back to control levels 5 days after the s.c. injection ( Figure 4C).
• LMW hyaluronic acid oligosaccharide derivatives do not induce spleen swelling
• CFU colony-forming unit
• LMW sulphated hyaluronic acid oligosaccharides synergizes with G-CSF to mobilize hematopoietic progenitor cells, but do not further increase the amounts of granulocytes
• HSCs hematopoietic stem cell
• CFU colony-forming unit
• LTR-HSCs long-term repopulating hematopoietic stem cells
• SLAM signaling lymphocyte activation molecule
• 6-O-S LMW HA injection in the G-CSF + 6-O-S LMW HA group As presented in Figure 14, the levels of circulating SLAM+ cells were dramatically increased in pegfilgrastim treated mice as compared to control (vehicle) mice levels. SLAM+ cells were also present when the animals received combination therapy with both pegfilgrastim and a single dose of 6-O- S LMW HA one hour before sampling. The analyzed cell population is encircled in insets A. and B. in Figure 14. EXAMPLE 7
• CFU colony forming-unit
• the levels of CD45+CD1 15+ progenitors were increased by the G- CSF stimulation and a combination of G-CSF + 6-O-S LMW HA made the increase of this progenitor pool statistically significant as compared to the levels in vehicle animals (Figure 12A).
• the levels of CD45+CD41 + progenitors were decreased from control levels in both G-CSF and G-CSF + 6-O-S LMW HA treatments ( Figure 12B).
• the levels of Ter-1 19+ proerythroblasts were seen to decrease after G-CSF treatment, but the combination of G-CSF + 6-O- S LMW HA could bring the proerythroblast levels back to control levels (Figure 12C).
• peripheral blood lymphocytes were increased due to G-CSF stimulation and combination with G-CSF + 6-O-S LMW HA caused a statistically significant increase in the total levels of lymphocytes as compared to control (vehicle) levels ( Figure 13A).
• the levels of CD3+ T-cells, NK (CD314+) cells, CD45R+ B-cells and lymphoid dendritic cells (CD1 1 c+) were determined separately as presented in Figures 13 B-E.
• G-CSF and G-CSF + 6-O-S LMW HA caused specific effects on the CD3+ T-cells, CD45R+ B-cells and lymphoid dendritic cell (CD1 1 c+) levels, especially concerning the lymphoid dendritic cells where a combination of G- CSF + 6-O-S LMW HA caused a significant increase in CD1 1 c+ cells as compared to control levels ( Figure 13E). The NK cell levels remained unaltered ( Figure 13C).
• 6-O-S LMW HA can induce proliferation of erythrocyte precursor cells in G-CSF treatments
• Macromolecular hyaluronic acid sodium salt from Streptococcus sp. (Calbiochem, Cat. No. 385908) was treated by mild aqueous acid hydrolysis according to standard procedure in controlled reaction to prepare smaller mo- lecular weight hyaluronic acid fragments.
• the product was purified and fractionated by size exclusion high performance liquid chromatography (HPLC) with preparative Supedex column (GE Healthcare) in aqueous ammonium bicarbonate buffer as shown in Figure 15. Fractions (see Table 1 ) were evaporated to dryness, dissolved in water and analyzed by MALDI-TOF mass spec- trometry according to standard procedure to determine their composition.
• the acid-hydrolyzed polymer fragments were shown to be HexNAc n HexA n components (with disaccharide repeats).
• the GlcNAc deacetylation degree was between 7% and 10%.
• the composition of the fractions selected for the pooled preparate are shown in Table 1 .
• the pooled preparate was a mixture of polymers with 10-46 monomers (10 mer to 46 mer), peaking at 16 mer to 18 mer.
• 60% of the material was 10 mer to 18 mer, 24% was 20 mer to 28 mer, and 16% was 30 mer to 46 mer.
• 75% of the material was 10mer to 18 mer, 17% was 20 mer to 28mer, and 8% was 30mer to 46mer.
• Relative proportions of smaller fragments were greater than those of larger fragments; for example, relative proportion of 10mer fragments was over 10% of the preparate by weight, while relative proportion of 46mer fragments was about 0.1 % of the preparate by weight.
• the GlcA groups were changed into sodium salt by adding an equimolar amount of sodium salt solution and evaporating to dryness.
• the preparate was dissolved in phosphate buffered saline (PBS) and sterile-filtered according to standard procedure.
• Figure 2A shows the size exclusion HPLC chromatogram of the pooled preparate.
• the preparate was further analyzed by proton nuclear magnetic resonance spectroscopy (NMR) in D 2 O according to standard procedures and using internal acetone as reference. By proton NMR, the preparate was determined identical to hyaluronic acid. It was also determined that the preparate was essentially homogeneous with regard to its reducing and non-reducing ends: reducing end monosaccharide was GlcNAc and the non-reducing end monosaccharide was GlcA.
• the GlcNAc deacetylation level was defined to be less than 2%, and the polymer preparate was shown to be a mixture of HexNAc n HexA n and HexNAc n- HexAn+1 components (mixture of components with either GlcNAc or GlcA as a terminal monosaccharide).
• the preparate was dissolved in phosphate buffered saline (PBS) and sterile-filtered according to standard procedure. Table 1. Composition of the pooled fractions from acid-hydrolyzed hyaluronic acid preparate
• Figure 16C shows the gel permeation HPLC chromatogram of another preparate with 50% O-sulfation degree. This sulfated product had similar elution position as the non-sulfated starting material (Fig. 16B), indicating that the two products had similar Stokes radius in aqueous solution.
• the preparate was dissolved in phosphate buffered saline (PBS) and sterile-filtered.
• PBS phosphate buffered saline
• HPCs hematopoietic progenitor cells
• mice were culled and blood was collected. The number of progenitor cells in the blood was determined using colony forming unit assay (CFU; similar procedure has been described: Pitchford et al. Cell Stem Cell 4:62-72, 2009).
• CFU colony forming unit assay
• FIG. 17 shows the results of the experiment, i.e., mobilization of hematopoietic progenitor cells in the bloodstream of mice as determined by colony forming unit (CFU) assay (y-axis).
• CFU colony forming unit
• the present HAmer product are radiolabelled by chemical modification with a radiolabelled molecule.
• the radiolabelling processes are obvious for a skilled person and may include labeling with e.g Carbon-14 (C14) labelled acetate to free amine groups of the molecule, labeling with Carbon-14 or Tritium (H3) labeled monosaccharides if synthesising the HAmer by a synthase enzyme (e.g. by methods of De Angelis and colleagues, Oklahoma, US) or attaching a radio-Iodine carrying molecule such as tyrosine e.g. by a reacting amine to reducing end of a present product in a reducing form.
• C14 Carbon-14
• H3 Tritium
• the product is administered to the subject or test animal as defined in examples and the radioactive product is measured from the harvested cells e.g. by liquid scintillation counting or for iodine by a gamma counter.
• the HAmer product can be isolated from the cells by extraction with water of buffer such as bicarbonate buffer, and characterized by gel filtration as shown HAmer characterization examples. It will be obvious to a person skilled in the art that, as the technology advances, the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described above but may vary within the scope of the claims.

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=42562985

Family Applications (3)

Family Applications Before (2)

Country Status (2)

Families Citing this family (5)

Family Cites Families (10)

• 2010
  • 2010-05-06 EP EP10162117A patent/EP2384759A1/de not_active Withdrawn
• 2011
  • 2011-05-06 EP EP11165109A patent/EP2384760A1/de not_active Withdrawn
  • 2011-05-06 WO PCT/FI2011/050423 patent/WO2011138512A1/en active Application Filing
  • 2011-05-06 EP EP11723491A patent/EP2566486A1/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events